ArticleJournal of fluorescence2011
Bioconjugated fluorescent polymeric nanoparticles for imaging and targeted therapy of HER2-overexpressing cancer cells.
Article in Journal of fluorescence, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 13 citations in OpenAlex.
- Strategies for Precise Engineering and Conjugation of Antibody Targeted-nanoparticles for Cancer Therapy.Current medical science · 2020Review
- A rhodamine-cyclen conjugate as chromogenic and fluorescent chemosensor for copper ion in aqueous media.Journal of fluorescence · 2013Article
- Nanomaterials for photo-based diagnostic and therapeutic applications.Theranostics · 2013Review
- Folate conjugated chitosan grafted thiazole orange derivative with high targeting for early breast cancer cells diagnosis.Journal of fluorescence · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the development of Herceptin-conjugated fluorescent polymeric nanoparticles (PNp) probes. Synthesis of fluorescent conjugated polymer as the core, preparation of the core/shell PNp, the ability of immobilizing Herceptin on PNp, targeting and imaging of bioconjugated PNp toward HER2-overexpressing cancer cells, and therapeutic effect on cell cycle, together with the expression of apoptosis related proteins, were investigated. We have achieved active tumor targeting by rapid PNp-antibody binding to tumor-specific antigens. Besides, Herceptin-conjugated PNp can suppress the growth of HER2-overexpressing cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.